View Item 

Show simple item record

Renal complications of lipodystrophy: A closer look at the natural history of kidney disease
dc.contributor.authorAkinci, Baris
dc.contributor.authorUnlu, Sadiye Mehtat
dc.contributor.authorCelik, Ali
dc.contributor.authorSimsir, Ilgin Yildirim
dc.contributor.authorSen, Sait
dc.contributor.authorNur, Banu
dc.contributor.authorKeskin, Fatma Ela
dc.contributor.authorOzgen Saydam, Basak
dc.contributor.authorKutbay Ozdemir, Nilufer
dc.contributor.authorSarer Yurekli, Banu
dc.contributor.authorErgur, Bekir Ugur
dc.contributor.authorSonmez, Melda
dc.contributor.authorAtik, Tahir
dc.contributor.authorArslan, Atakan
dc.contributor.authorDemir, Tevfik
dc.contributor.authorAltay, Canan
dc.contributor.authorTunc, Ulku Aybuke
dc.contributor.authorArkan, Tugba
dc.contributor.authorGen, Ramazan
dc.contributor.authorEren, Erdal
dc.contributor.authorAkinci, Gulcin
dc.contributor.authorYilmaz, Aslihan Arasli
dc.contributor.authorBilen, Habib
dc.contributor.authorOzen, Samim
dc.contributor.authorCeltik, Aygul
dc.contributor.authorSavas Erdeve, Senay
dc.contributor.authorCetinkaya, Semra
dc.contributor.authorOnay, Huseyin
dc.contributor.authorSarioglu, Sulen
dc.contributor.authorOral, Elif Arioglu
dc.date.accessioned2018-07-13T15:46:53Z
dc.date.available2019-09-04T20:15:39Zen
dc.date.issued2018-07
dc.identifier.citationAkinci, Baris; Unlu, Sadiye Mehtat; Celik, Ali; Simsir, Ilgin Yildirim; Sen, Sait; Nur, Banu; Keskin, Fatma Ela; Ozgen Saydam, Basak; Kutbay Ozdemir, Nilufer; Sarer Yurekli, Banu; Ergur, Bekir Ugur; Sonmez, Melda; Atik, Tahir; Arslan, Atakan; Demir, Tevfik; Altay, Canan; Tunc, Ulku Aybuke; Arkan, Tugba; Gen, Ramazan; Eren, Erdal; Akinci, Gulcin; Yilmaz, Aslihan Arasli; Bilen, Habib; Ozen, Samim; Celtik, Aygul; Savas Erdeve, Senay; Cetinkaya, Semra; Onay, Huseyin; Sarioglu, Sulen; Oral, Elif Arioglu (2018). "Renal complications of lipodystrophy: A closer look at the natural history of kidney disease." Clinical Endocrinology 89(1): 65-75.
dc.identifier.issn0300-0664
dc.identifier.issn1365-2265
dc.identifier.urihttps://hdl.handle.net/2027.42/144612
dc.publisherWiley Periodicals, Inc.
dc.subject.otherinsulin resistance
dc.subject.otherproteinuria
dc.subject.otherchronic kidney disease
dc.subject.otherlipodystrophy
dc.titleRenal complications of lipodystrophy: A closer look at the natural history of kidney disease
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelInternal Medicine and Specialties
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/144612/1/cen13732_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/144612/2/cen13732.pdf
dc.identifier.doi10.1111/cen.13732
dc.identifier.sourceClinical Endocrinology
dc.identifier.citedreferenceExpert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285: 2486 ‐ 2497.
dc.identifier.citedreferenceLevey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150: 604 ‐ 612.
dc.identifier.citedreferenceGross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005; 28: 164 ‐ 176.
dc.identifier.citedreferenceAkinci B, Onay H, Demir T, et al. Clinical presentations, metabolic abnormalities and end‐organ complications in patients with familial partial lipodystrophy. Metabolism. 2017; 72: 109 ‐ 119.
dc.identifier.citedreferenceAkinci B, Onay H, Demir T, et al. Natural history of congenital generalized lipodystrophy: a nationwide study from Turkey. J Clin Endocrinol Metab. 2016; 101: 2759 ‐ 2767.
dc.identifier.citedreferenceCheong B, Muthupillai R, Rubin MF, Flamm SD. Normal values for renal length and volume as measured by magnetic resonance imaging. Clin J Am Soc Nephrol. 2007; 2: 38 ‐ 45.
dc.identifier.citedreferenceHogg RJ, Portman RJ, Milliner D, Lemley KV, Eddy A, Ingelfinger J. Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE). Pediatrics. 2000; 105: 1242 ‐ 1249.
dc.identifier.citedreferenceStevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013; 158: 825 ‐ 830.
dc.identifier.citedreferenceSchwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol. 2009; 4: 1832 ‐ 1843.
dc.identifier.citedreferencePatni N, Garg A. Congenital generalized lipodystrophies‐new insights into metabolic dysfunction. Nat Rev Endocrinol. 2015; 11: 522 ‐ 534.
dc.identifier.citedreferencePeters JM, Barnes R, Bennett L, Gitomer WM, Bowcock AM, Garg A. Localization of the gene for familial partial lipodystrophy (Dunnigan variety) to chromosome 1q21‐22. Nat Genet. 1998; 18: 292 ‐ 295.
dc.identifier.citedreferenceMisra A, Peethambaram A, Garg A. Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature. Medicine (Baltimore). 2004; 83: 18 ‐ 34.
dc.identifier.citedreferenceMusso C, Javor E, Cochran E, Balow JE, Gorden P. Spectrum of renal diseases associated with extreme forms of insulin resistance. Clin J Am Soc Nephrol. 2006; 1: 616 ‐ 622.
dc.identifier.citedreferenceJavor ED, Moran SA, Young JR, et al. Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy. J Clin Endocrinol Metab. 2004; 89: 3199 ‐ 3207.
dc.identifier.citedreferenceImachi H, Murao K, Ohtsuka S, et al. A case of Dunnigan‐type familial partial lipodystrophy (FPLD) due to lamin A/C (LMNA) mutations complicated by end‐stage renal disease. Endocrine. 2009; 35: 18 ‐ 21.
dc.identifier.citedreferenceKlupa T, Szopa M, Skupien J, et al. LMNA gene mutation search in Polish patients: new features of the heterozygous Arg482Gln mutation phenotype. Endocrine. 2009; 36: 518 ‐ 523.
dc.identifier.citedreferenceLudtke A, Roos GM, van Hettinga M, Horst BA, Worman HJ, Schmidt HH. Post‐mortem findings in Dunnigan‐type familial partial lipodystrophy. Diabet Med. 2010; 27: 245 ‐ 246.
dc.identifier.citedreferenceAmerican Diabetes Association. Standards of medical care in diabetes–2014. Diabetes Care 2014; 37 ( Suppl 1 ): S14 ‐ S80.
dc.identifier.citedreferenceExpert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011; 128 ( Suppl 5 ): S213 ‐ S256.
dc.identifier.citedreferenceSimsir IY, Yurekli BS, Saygili F, Altay C, Akinci B. First metreleptin treatment for generalized lipodystrophy in Turkey. Diabetes Obes Metab. 2017; 19: 299 ‐ 301.
dc.identifier.citedreferenceChong AY, Lupsa BC, Cochran EK, Gorden P. Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia. 2010; 53: 27 ‐ 35.
dc.identifier.citedreferenceEbihara K, Kusakabe T, Hirata M, et al. Efficacy and safety of leptin‐replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J Clin Endocrinol Metab. 2007; 92: 532 ‐ 541.
dc.identifier.citedreferenceJiang T, Wang Z, Proctor G, et al. Diet‐induced obesity in C57BL/6J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element‐binding protein‐1c‐dependent pathway. J Biol Chem. 2005; 280: 32317 ‐ 32325.
dc.identifier.citedreferenceSun L, Halaihel N, Zhang W, Rogers T, Levi M. Role of sterol regulatory element‐binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J Biol Chem. 2002; 277: 18919 ‐ 18927.
dc.identifier.citedreferenceD’Agati VD, Chagnac A, de Vries AP, et al. Obesity‐related glomerulopathy: clinical and pathologic characteristics and pathogenesis. Nat Rev Nephrol. 2016; 12: 453 ‐ 471.
dc.identifier.citedreferenceErtunc ME, Hotamisligil GS. Lipid signaling and lipotoxicity in metaflammation: indications for metabolic disease pathogenesis and treatment. J Lipid Res. 2016; 57: 2099 ‐ 2114.
dc.identifier.citedreferenceThong KM, Xu Y, Cook J, et al. Cosegregation of focal segmental glomerulosclerosis in a family with familial partial lipodystrophy due to a mutation in LMNA. Nephron Clin Pract. 2013; 124: 31 ‐ 37.
dc.identifier.citedreferenceKambham N, Markowitz GS, Valeri AM, Lin J, D’Agati VD. Obesity‐related glomerulopathy: an emerging epidemic. Kidney Int. 2001; 59: 1498 ‐ 1509.
dc.identifier.citedreferenceGuebre‐Egziabher F, Alix PM, Koppe L, et al. Ectopic lipid accumulation: a potential cause for metabolic disturbances and a contributor to the alteration of kidney function. Biochimie. 2013; 95: 1971 ‐ 1979.
dc.identifier.citedreferenceHaque WA, Vuitch F, Garg A. Post‐mortem findings in familial partial lipodystrophy Dunnigan variety. Diabet Med. 2002; 19: 1022 ‐ 1025.
dc.identifier.citedreferenceJerums G, Premaratne E, Panagiotopoulos S, MacIsaac RJ. The clinical significance of hyperfiltration in diabetes. Diabetologia. 2010; 53: 2093 ‐ 2104.
dc.identifier.citedreferenceDiez‐Sampedro A, Lenz O, Fornoni A. Podocytopathy in diabetes: a metabolic and endocrine disorder. Am J Kidney Dis. 2011; 58: 637 ‐ 646.
dc.identifier.citedreferenceArtunc F, Schleicher E, Weigert C, Fritsche A, Stefan N, Häring HU. The impact of insulin resistance on the kidney and vasculature. Nat Rev Nephrol. 2016; 12: 721 ‐ 737.
dc.identifier.citedreferenceAkinci B, Koseoglu FD, Onay H, et al. Acquired partial lipodystrophy is associated with increased risk for developing metabolic abnormalities. Metabolism. 2015; 64: 1086 ‐ 1095.
dc.identifier.citedreferenceOwen KR, Donohoe M, Ellard S, et al. Mesangiocapillary glomerulonephritis type 2 associated with familial partial lipodystrophy (Dunnigan‐Kobberling syndrome). Nephron Clin Pract. 2004; 96: c35 ‐ c38.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cen13732_am.pdf
Size:
319.1KB
Format:
PDF
View/Open
Name:
cen13732.pdf
Size:
729.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.